Newsroom Articles

Explore Ionis' 2025 Corporate Responsibility Report — covering RNA-targeted medicine breakthroughs, ESG commitments, employee impact, and sustainability milestones.

March marks Amyloidosis Awareness Month. We sat down with Charles, an 88-year-old retired cardiologist from Massachusetts, who shared what it’s like to diagnose and treat heart disease for decades and then face a diagnosis himself. His experience with transthyretin amyloid cardiomyopathy (ATTR-CM) offers a unique perspective on this underrecognized condition.

2025 was a defining year for Ionis, hallmarked by our first two independent launches as a commercial stage biotech company. Now, Ionis is poised for another transformative year - at JPM 2026 we shared highlights from the past year and outlined key anticipated milestones.

Rick has experienced symptoms of FCS his entire life. He has been hospitalized more times than he can count with acute pancreatitis and describes it as the most pain he has ever been in. Despite these challenges, Rick is hopeful about the future for people living with this rare and severe disease and passionate about helping other people with FCS.

Recognizing our industry-leading scientific innovation and company culture, Science magazine ranked Ionis their #2 Top Employer in 2025.

Hear Dr. Sam Tsimikas, SVP of Global Cardiovascular Development, share how Ionis is redefining cardiometabolic care.

Ionis is proud to announce that we have ranked #6 on the San Diego Business Journal’s 2025 Best Places to Work list in the Large Companies category. This marks our second consecutive year being recognized and our first year breaking into the Top 10…

Ionis CEO Brett Monia, Ph.D. shares the journey to becoming a fully integrated biotech, advancing RNA-targeted medicines and delivering greater impact for patients.